pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 44
- Patents
- 0
Hexaxim®
Phase 3 · mab · Diphtheria
Hexaxim® for Diphtheria is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code A3L35
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- mab
- Indication
- Diphtheria
- Status
- completed
- Trials
- 1